|
|
|
| 5/27/2010 |
President Obama under fire for BP spill response President Barack Obama is on the defensive over his presidential multitasking, for refusing to scrub his schedule of events that seem peripheral — even trivial — compared with the unfolding catastrophe in the Gulf of Mexico. As oozing oil fouls Louisiana’s marshes, Obama has committed to maintaining the semblance of a regular schedule, adhering to his walk-and-chew-gum style of crisis management even as criticism of his administration mounts. (Politico) | |||
| + Show URL & ALL Tags | ||||
| ||||
keywords: Barack Obama, Barbara Boxer, Big Oil, Bill Clinton, Bobby Jindal, British Petroleum, Coal, Dana Perino, Daniel Kessler, Darrell Issa, Debbie Stabenow, Deepwater Horizon, Dick Cheney, Fox, George W Bush, Greenpeace, Gulf Of Mexico, Hurricane Katrina, James Carville, Louisiana, New Orleans, North Korea, Oil Spill, Ronald Reagan, San Francisco, Sean Hannity, South Korea, US Congress, United States, Washington DC, West Virginia, White House
| ||||
| 1/30/2010 |
The Sharp Dressed Man Who Aided Mutallab Onto Flight 253 Was U.S. Government Agent I asked the FBI if they brought the Amsterdam security video to help me identify the SDM, but they acted as though my request was ridiculous. (Prison Planet) | |||
| + Show URL & ALL Tags | ||||
| ||||
keywords: Airports, Al-qaeda, Amsterdam, Carl Levin, Christmas Day Bombing Attempt, Debbie Stabenow, Detroit MI, Federal Bureau Of Investigation, Janet Napolitano, John Dingell, Keith Olbermann, Kurt Haskell, Michael Leiter, National Counterterrorism Center, Netherlands, Patrick F Kennedy, Privacy, Richard Wolffe, Terrorists, US Congress, US Department Of Homeland Security, US Department Of State, Umar Farouk Abdulmutallab, United States, X-ray
| ||||
| 3/9/2009 |
Who Pays for Cap and Trade? Hint: They were promised a tax cut during the Obama campaign Cap and trade, in other words, is a scheme to redistribute income and wealth -- but in a very curious way. It takes from the working class and gives to the affluent (Wall Street Journal) | |||
| + Show URL & ALL Tags | ||||
| ||||
| 2/9/2009 |
Talk radio: The return of 'fairness'? For five days, Sen. Debbie Stabenow’s face has greeted visitors of Hannity.com. It may seem like an unlikely venue for a Michigan Democrat, but conservative television and radio host Sean Hannity has made Stabenow public enemy No. 1 in the conservative talk radio world. Hannity has plastered Stabenow’s face and office number on his site following comments she made last week about the Fairness Doctrine, telling liberal radio host Bill Press it may be “time to be bringing accountability to the airwaves.” And then she mentioned the possibility of hearings, which sparked a make-my-day moment with Hannity, who said, “You want this microphone? Come and get it!” Stabenow press secretary Brad Carroll has since backed off, telling Politico, “Sen. Stabenow is not calling for hearings.” Indeed, no member of Congress has scheduled hearings, there is no Fairness Doctrine legislation being introduced, and the long-dormant broadcast law is likely to stay that way. (Politico) | |||
| + Show URL & ALL Tags | ||||
| ||||
keywords: Bill Hemmer, Broadcasting & Cable, Charles Schumer, Debbie Stabenow, Dick Durbin, Fairness Doctrine, Federal Communications Commission, Michael Harrison, Mike Pence, Nancy Pelosi, Rachel Maddow, Rush Limbaugh, Sean Hannity, US Congress, United States
| ||||
| 10/27/2004 |
The Hidden Soros Agenda: Drugs, Money, the Media, and Political Power His complex web of financial interests, companies and foundations makes Halliburton look like a Mom & Pop operation. (Accuracy In Media) | |||
| + Show URL & ALL Tags | ||||
| ||||
keywords: 9/11, Al Gore, Allen St Pierre, American Civil Liberties Union, Bank Of England, Barack Obama, Barbara Boxer, Bill Clinton, Bill Moyers, Bob Graham, Brad Carson, Carl Levin, Center For Public Integrity, Central Intelligence Agency, Charles Schumer, Cold War, Colombia, Commodity Futures Trading Commission, Council On Foreign Relations, Debbie Stabenow, Dennis Hastert, Dick Cheney, Donald Rumsfeld, Drug Cartels, Drug Enforcement Administration, Drug Policy Alliance, Eliot Spitzer, Ethan Nadelmann, France, George Soros, George W Bush, Halliburton, Hillary Clinton, Howard Dean, Human Rights Watch, Iraq, John Corzine, John Kerry, Joseph Biden, Kofi Annan, Kosovo, Lyndon Johnson, Marijuana, Mary Landrieu, Money Laundering, National Organization For The Reform Of Marijuana Laws, New Zealand, Open Society Institute, Patrick Leahy, Paul Sarbanes, Religion, Securities And Exchange Commission, Serbia, Terrorists, Thomas Daschle, Thomas Harkin, Tom Coburn, United Kingdom, United Nations, United States, US Supreme Court, Wall Street, War On Drugs, Weather Underground, Wesley Clark, White House, Yugoslavia
| ||||
| 7/15/2004 |
The Truth About the Drug Companies Every day Americans are subjected to a barrage of advertising by the pharmaceutical industry. Mixed in with the pitches for a particular drug—usually featuring beautiful people enjoying themselves in the great outdoors—is a more general message. Boiled down to its essentials, it is this: “Yes, prescription drugs are expensive, but that shows how valuable they are. Besides, our research and development costs are enormous, and we need to cover them somehow. As ‘research-based’ companies, we turn out a steady stream of innovative medicines that lengthen life, enhance its quality, and avert more expensive medical care. You are the beneficiaries of this ongoing achievement of the American free enterprise system, so be grateful, quit whining, and pay up.” More prosaically, what the industry is saying is that you get what you pay for. Is any of this true? Well, the first part certainly is. Prescription drug costs are indeed high—and rising fast. Americans now spend a staggering $200 billion a year on prescription drugs, and that figure is growing at a rate of about 12 percent a year (down from a high of 18 percent in 1999).1 Drugs are the fastest-growing part of the health care bill—which itself is rising at an alarming rate. The increase in drug spending reflects, in almost equal parts, the facts that people are taking a lot more drugs than they used to, that those drugs are more likely to be expensive new ones instead of older, cheaper ones, and that the prices of the most heavily prescribed drugs are routinely jacked up, sometimes several times a year. Before its patent ran out, for example, the price of Schering-Plough’s top-selling allergy pill, Claritin, was raised thirteen times over five years, for a cumulative increase of more than 50 percent—over four times the rate of general inflation.2 As a spokeswoman for one company explained, “Price increases are not uncommon in the industry and this allows us to be able to invest in R&D.”3 In 2002, the average price of the fifty drugs most used by senior citizens was nearly $1,500 for a year’s supply. (Pricing varies greatly, but this refers to what the companies call the average wholesale price, which is usually pretty close to what an individual without insurance pays at the pharmacy.) This is an industry that in some ways is like the Wizard of Oz—still full of bluster but now being exposed as something far different from its image. Instead of being an engine of innovation, it is a vast marketing machine. Instead of being a free market success story, it lives off government-funded research and monopoly rights. Yet this industry occupies an essential role in the American health care system, and it performs a valuable function, if not in discovering important new drugs at least in developing them and bringing them to market. But big pharma is extravagantly rewarded for its relatively modest functions. We get nowhere near our money’s worth. The United States can no longer afford it in its present form. (The New York Review of Books) | |||
| + Show URL & ALL Tags | ||||
| ||||
keywords: Arthritis, Astrazeneca, Aventis, Bayh-dole Act, Big Oil, Big Pharma, Bill Clinton, Birch Bayh, Bob Dole, Bristol-myers Squibb, Canada, Celebrex, Charles A Heimbold Jr, Cholesterol, Claritin, Crestor, DNA, Debbie Stabenow, Diabetes, European Union, Families Usa, France, George W Bush, Glaxosmithkline, Glucophage, Hatch-waxman Act, Health Care, Henry Waxman, Ims Health, Internet, Johnson & Johnson, Kaiser Permanente, Lescol, Lipitor, Lupron, Medicaid, Medicare, Merck, Mevacor, Mexico, National Institutes Of Health, Novartis, Orrin Hatch, Pfizer, Pravachol, Prilosec, Prozac, Roche, Ronald Reagan, Sanafi Synthelabo, Schering-plough, Securities And Exchange Commission, Switzerland, Tap Pharmaceuticals, US Congress, US Department Of Veterans Affairs, US Food And Drug Administration, US Patent And Trade Office, US Supreme Court, United Kingdom, United States, Wall Street, World War II, Wyeth, Zocor, Zoloft
| ||||